BioTech startup Synthace gets £7.3m Series A

Sep 20, 2017 · uktech.news

BioTech firm Synthace has raised £7.3m in Series A funding from investors including White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital.

Existing shareholders Sofinnova Partners, SOSV and Bioeconony Capital also participated.

The company, which has created proprietary language and software platform Antha specifically for biologists, says it will use the cash to gain further traction and expand in the market.

Antha, the company says, is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment.

Synthace CEO Tim Fell said: "Our need to heal, feed, fuel and manufacture for a growing population can be met by unlocking the near infinite power of biology but only by bringing software abstraction and more automation to biological R&D and manufacturing, and by enabling biologists to build atop their collective work. That is what the Antha platform does, and why we are so passionate about realizing its potential."

Read Complete Article

RT @dannyatbartlett: From Unicorn Start-up to Tech Phoenix: Four guiding principles that helped Ve Global rise from the ashes after failure…

London stands with New York against terrorism today and always. Those who seek to harm us, destroy our way of life… https://t.co/upGKL5LXie

Check out the on-demand webinar hosted by @Genesys and @DimensionData to understand how #Cloud and #CX can work tog… https://t.co/IQgCdgeqio

City would be wise to watch Bitcoin bubble from sidelines #Premium https://t.co/VBCjSbE3Fn

🙌 Zing! 🙌 @oht_uk are hiring a Community Manager https://t.co/Y0MEK0PxE3 #jobs #community

Tech.London Weekly

×